{"id":368295,"date":"2023-12-01T20:18:35","date_gmt":"2023-12-02T01:18:35","guid":{"rendered":"https:\/\/platohealth.ai\/what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer\/"},"modified":"2023-12-02T22:30:31","modified_gmt":"2023-12-03T03:30:31","slug":"what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/what-a-pair-of-phase-ii-obesity-results-could-mean-for-altimmune-pfizer\/","title":{"rendered":"What a pair of Phase II obesity results could mean for Altimmune, Pfizer\u00a0","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
ARTICLE | Product Development<\/p>\n
\n By\u00a0<\/span>Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst<\/span>\n<\/p>\n December 2, 2023 1:18 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n Neither of Friday\u2019s Phase II obesity readouts, one from Altimmune and one from Pfizer, pointed to best-in-class potential. However, with efficacy similar to Wegovy, Altimmune could be positioned to partner. Pfizer, by contrast, has paused its twice-daily danuglipron program, which could send the pharma shopping for a new therapy.\u00a0<\/p>\n After opening Friday up 82%, shares of Altimmune Inc.<\/a> (NASDAQ:ALT) finished the day up 13%, giving the company a market cap of about $192 million, as investors digested results from the Phase II MOMENTUM trial of pemvidutide. <\/span>…<\/p>\n ARTICLE | Product Development Will\u00a0Altimmune\u2019s pemvidutide be good enough to attract a partner? And will\u00a0Pfizer go shopping after latest danuglipron data? By\u00a0Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst December 2, 2023 1:18 AM UTC Neither of Friday\u2019s Phase II obesity readouts, one from Altimmune and one from Pfizer, pointed to best-in-class potential. […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":368299,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/368295"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=368295"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/368295\/revisions"}],"predecessor-version":[{"id":368298,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/368295\/revisions\/368298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/368299"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=368295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=368295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=368295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<\/span><\/div>\n
\n